News

Takeda will receive $266m upfront in cash and up to an additional $12 million USD in potential milestone payments, subject to customary legal and regulatory closing conditions. The

ATHENA is the first front-line switch maintenance study designed to show PARP monotherapy and PARP/PD-1 combination therapy in one study design. “The completion of target patient enrollment in

“Up to twenty percent of children are affected by atopic dermatitis and there remains a significant unmet need for new treatment options that may improve their care,” said

The approval allows Kalydeco to be used for the treatment of children and adolescents with CF aged between six months and older with a weight of at least

Autobahn Therapeutics is launching to create the next generation of regenerative medicines to restore hope for people affected by CNS disorders. The company has completed a $76 million

The collaboration will evaluate Lyvgen’s LVGN6051, a second generation 4-1BB (CD137) agonist antibody, in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in a Phase 1 study in adult

The partnership will assess the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product DRibble Platform Vaccine 001(DPV-001) in combination with BMS’ anti-OX40 (BMS-986178) combined with sequenced administration

The investment will be made in the Danish site of FUJIFILM Diosynth Biotechnologies with an aim to double the drug substance production capacity of the biologics production facility.

According to IGY Life Sciences, the partnership with the clinical data and regulatory expert will focus on the nasal spray application of IgY-110, which it expects to be